Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.43 USD | +3.42% | +3.65% | +8.17% |
May. 30 | Baird Starts Astrana Health With Outperform Rating, $54 Price Target | MT |
May. 16 | Transcript : Astrana Health, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The firm trades with high earnings multiples: 27.02 times its 2024 earnings per share.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.17% | 2.03B | D+ | ||
+25.52% | 88.99B | C+ | ||
-24.52% | 74.82B | B- | ||
-5.56% | 25.03B | C+ | ||
+4.31% | 17.88B | A- | ||
-14.25% | 16.43B | B | ||
+2.97% | 15.77B | A- | ||
+79.20% | 13.21B | C+ | ||
+70.11% | 13.09B | C- | ||
+40.44% | 12.9B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ASTH Stock
- Ratings Astrana Health, Inc.